AzTrials
AzTrials

MyopiaNCT04585646

A Two-Week Crossover Dispensing Evaluation Of Orion Daily Wear Soft Contact Lens

A study testing Orion daily disposable contact lens and Gemini daily disposable contact lens in people with Myopia, run by CooperVision, Inc. at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The primary objective of the study is to evaluate the clinical performance of test lens (Orion) in comparison with control lens (Gemini) over a period of two weeks of wear. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Myopia
What is being tested?
Orion daily disposable contact lens and Gemini daily disposable contact lens
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
64 participants
Where
1 siteUnited States
Study dates
14 Sep 2020to 31 Dec 2020
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Is at least 18 years of age and has full legal capacity to volunteer.
  • Is no greater than 55 years of age.
  • Has read and understood the information consent letter.
  • Is willing and able to follow instructions and maintain the appointment schedule.
  • Is an adapted soft contact lens wearer having worn lenses for a minimum of 4 weeks prior to the study.
  • Has spectacle cylinder ≤1.00D in both eyes.
Show all 12Show fewer
  • Has spherical contact lens power requirement between -1.00D and -6.00D in both eyes.
  • Has manifest refraction visual acuities (VA) equal to or better than logMAR equivalent of 20/20 in each eye.
  • Wears CLs in both eyes (monovision acceptable, but not monofit)
  • Has clear corneas and no active ocular disease.
  • Has not worn lenses for at least 12 hours before the examination.
  • Is willing to wear the study contact lenses for a minimum 8 hours per day/6 days per week

Who cannot join

  • Has never worn contact lenses before.
  • Has any systemic disease affecting ocular health.
  • Is using any systemic or topical medications that will affect ocular health.
  • Has any ocular pathology or severe insufficiency of lacrimal secretion (moderate to severe dry eyes) that would affect the wearing of contact lenses.
  • Has persistent, clinically significant corneal or conjunctival staining using sodium fluorescein dye.
  • Has any clinically significant lid or conjunctival abnormalities, active neovascularization or any central corneal scars.
Show all 11Show fewer
  • Is aphakic.
  • Has strabismus/amblyopia.
  • Has undergone corneal refractive surgery.
  • Is pregnant, lactating or planning a pregnancy.
  • Is participating in any concurrent clinical or research study.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • CORL, Indiana University

    Bloomington, Indiana, 47405

Other trials in United States

About this study

The primary objective of the study is to evaluate the clinical performance of test lens (Orion) in comparison with control lens (Gemini) over a period of two weeks of wear.

Read the detailed description

The primary objective of the study is to evaluate the clinical performance of test lens (Orion) in comparison with control lens (Gemini) over a period of two weeks of wear. This is a double-masked, randomized, bilateral, two-week crossover, dispensing study.

Conditions
Myopia
Being tested
Orion daily disposable contact lens, Gemini daily disposable contact lens
Medical subject headings
Myopia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Orion daily disposable contact lensDevice

    Subjects will be randomized to wear Orion lens for 2 weeks.

  • Gemini daily disposable contact lensDevice

    Subjects will be randomized to wear Gemini lens for 2 weeks.

Study groups in NCT04585646
Study groupRoleWhat they receive
Orion then GeminiExperimentalSubjects will be randomized to wear Orion daily disposable contact lens then Gemini daily disposable contact lens for 2 weeks in this randomized, cross-over bilateral dispensing study.
Receives: Device: Orion daily disposable contact lens; Device: Gemini daily disposable contact lens
Gemini then OrionExperimentalSubjects will be randomized to wear Gemini daily disposable contact lens then Orion daily disposable contact lens for 2 weeks in this randomized, cross-over bilateral dispensing study.
Receives: Device: Orion daily disposable contact lens; Device: Gemini daily disposable contact lens

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Subjective Response for Vision Satisfaction

    Subjective Response for Vision Satisfaction assessed on 7-point Likert (Very satisfied, Satisfied, Somewhat satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied)

    Measured: Baseline - After 10 minutes of lens dispense

  2. Subjective Response for Overall Vision Satisfaction

    Subjective Response for Vision satisfaction assessed on 7-point Likert (Very satisfied, Satisfied, Somewhat satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied)

    Measured: 2 Weeks

  3. Subjective Response for Overall Vision Satisfaction

    Subjective Response for Vision satisfaction assessed on 7-point Likert (Very satisfied, Satisfied, Somewhat satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied)

    Measured: 2 Weeks - at night

  4. Subjective Response for Overall Vision Quality

    Subjective Response for Overall Vision quality assessed on a 0-100 scale (0- Unacceptable, 100- Excellent Vision)

    Measured: Baseline - After 10 minutes of lens dispense

  5. Subjective Response for Overall Vision Quality

    Subjective Response for Overall Vision Quality assessed on a 0-100 scale (0- Unacceptable, 100- Excellent Vision)

    Measured: 2 weeks

  6. Subjective Response for Overall Vision Quality

    Subjective Response for Overall Vision Quality assessed on a 0-100 scale (0- Unacceptable, 100- Excellent Vision)

    Measured: 2 weeks - Night Driving

Secondary outcomes (19)
  1. Subjective Overall Comfort Satisfaction

    Overall comfort satisfaction analyzed on 7-point Likert (Very satisfied, Satisfied, Somewhat satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied)

    Measured: Baseline - After 10 minutes of lens dispense

  2. Subjective Overall Comfort Satisfaction

    Overall comfort satisfaction analyzed on 7-point Likert (Very satisfied, Satisfied, Somewhat satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied)

    Measured: 2 Weeks

  3. Subjective Preference for Comfort

    Subjective preference for comfort (Orion strongly, Orion slightly, No preference, Gemini slightly, Gemini strongly)

    Measured: 2 weeks

  4. Lens Surface Wettability Performance

    Lens Surface wettability performance was measured on a scale of 0-4, 0.25 steps (0-Very poor, 1 - Poor, 2- Acceptable, 3- Good, 4- Excellent)

    Measured: Baseline - After 10 minutes of lens dispense

  5. Lens Surface Wettability Performance

    Lens Surface wettability performance was measured on a scale of 0-4, 0.25 steps (0-Very poor, 1 - Poor, 2- Acceptable, 3- Good, 4- Excellent)

    Measured: 2 weeks

  6. Horizontal Lens Centration

    Horizontal Lens Centration assessed in primary gaze, white light, diffuse, low-medium magnification, with graticule on 0.1mm steps (Nasal decentration given +ve value. temporal decentration given -ve value)

    Measured: Baseline - After 10 minutes of lens dispense

  7. Horizontal Lens Centration

    Horizontal Lens Centration assessed in primary gaze, white light, diffuse, low-medium magnification, with graticule on 0.1mm steps (Nasal decentration given +ve value. temporal decentration given -ve value)

    Measured: 2 weeks

  8. Vertical Lens Centration

    Vertical Lens Centration assessed in primary gaze, white light, diffuse, low-medium magnification, with graticule on 0.1mm steps (Superior decentration given +ve value, inferior decentration given -ve value)

    Measured: Baseline - After 10 minutes of lens dispense

  9. Vertical Lens Centration

    Vertical Lens Centration assessed in primary gaze, white light, diffuse, low-medium magnification, with graticule on 0.1mm steps (Superior decentration given +ve value, inferior decentration given -ve value)

    Measured: 2 weeks

  10. Post-blink Movement

    Post-blink movement assessed on the amount of lens movement to the nearest 0.1mm immediately after the blink

    Measured: Baseline - after 10 minutes of lens dispense

  11. Post-blink Movement

    Post-blink movement assessed on the amount of lens movement to the nearest 0.1mm immediately after the blink

    Measured: 2 weeks

  12. Lens Horizontal Mobility Rating

    Lens Horizontal Mobility Rating on a scale of 0-4 (0-immobile, 1- restricted, 2- secure, 3- unrestricted, 4- very mobile)

    Measured: Baseline - after 10 minutes of lens dispense

  13. Lens Horizontal Mobility Rating

    Lens Horizontal Mobility Rating on a scale of 0-4 (0-immobile, 1- restricted, 2- secure, 3- unrestricted, 4- very mobile)

    Measured: 2 weeks

  14. Corneal Staining Extent

    Corneal staining extent will be assessed on a scale of 0-4 (0- No Staining, 1- 1 to 15% of area, 2- 16 to 30% of area, 3- 31-45% of area, 4- >45% of area).

    Measured: Baseline - after 10 minutes of lens dispense

  15. Corneal Staining Extent

    Corneal staining extent will be assessed on a scale of 0-4 (0- No Staining, 1- 1 to 15% of area, 2- 16 to 30% of area, 3- 31-45% of area, 4- >45% of area).

    Measured: 2 weeks

  16. Overall Lens Fit Acceptance

    Overall Lens Fit Acceptance assessed on a scale of 0-4 (0-Can't be worn, 1- Poor but acceptable, 2- Fair, 3- Good, 4- Optimum)

    Measured: Baseline - after 10 minutes of lens dispense

  17. Overall Lens Fit Acceptance

    Overall Lens Fit Acceptance assessed on a scale of 0-4 (0-Can't be worn, 1- Poor but acceptable, 2- Fair, 3- Good, 4- Optimum)

    Measured: 2 weeks

  18. Lens Handling Satisfaction

    Lens handling satisfaction assessed on a 7-point Likert Scales (Very satisfied, satisfied, Somewhat satisfied, Neither Satisfied nor Dissatisfied, Somewhat Dissatisfied, Dissatisfied, Very Dissatisfied)

    Measured: 2 weeks

  19. Subjective Overall Lens Handling

    SubjectiveOverall Lens handling assessed on a scale of 0-100 (0- cannot be managed, 100- Excellent handling)

    Measured: 2 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Oct 2020
  2. Study start14 Sep 2020
  3. Primary completion30 Nov 2020
  4. Study completion31 Dec 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
64 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04585646
Sponsor's protocol ID
CV-20-18
Status last verified
Apr 2022
First submitted
5 Oct 2020
Last updated
10 May 2022
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Orion daily disposable contact lens and Gemini daily disposable contact lens in people with Myopia, run by CooperVision, Inc. at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 12 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 10 May 2022). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Subjective Response for Vision Satisfaction (time frame: Baseline - After 10 minutes of lens dispense). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in